Ernexa director reports no ERNA share holdings

Director Robert J. Spiegel filed an initial Form 3 for Ernexa Therapeutics Inc. with no reportable share holdings or transactions.

Rhea-AI Filing Summary

Ernexa Therapeutics Inc. (ERNA) has a new initial insider ownership report. Director Robert J. Spiegel filed a Form 3 as a reporting person of the company. The filing lists no reportable transactions, derivative positions, or equity holdings for him as of the reporting date.

Key Figures

Buy transactions: 0 transactions Sell transactions: 0 transactions Holding entries: 0 positions

3 metrics

Buy transactions 0 transactions Insider transaction summary for Robert J. Spiegel on Form 3

Sell transactions 0 transactions Insider transaction summary for Robert J. Spiegel on Form 3

Holding entries 0 positions Number of reported equity or derivative holdings for Robert J. Spiegel

Key Terms

Form 3, reporting person, derivative positions

3 terms

Form 3 regulatory

"filed a Form 3 as a reporting person of the company"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

"filed a Form 3 as a reporting person of the company"

derivative positions financial

"no reportable transactions, derivative positions, or equity holdings"

Derivative positions are contracts that derive their value from an underlying asset—such as a stock, bond, currency or commodity—and include instruments like options, futures and swaps. Think of them as bets or insurance tied to an asset’s future price: they let investors amplify returns, hedge risk or take exposure without owning the asset directly, which can meaningfully increase potential gains, losses and volatility in a portfolio.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filed for ERNA by Robert J. Spiegel report?

The Form 3 for Ernexa Therapeutics Inc. (ERNA) identifies Robert J. Spiegel as a director and reporting person. It reports no transactions, no equity holdings, and no derivative positions for him as of the filing’s reporting date.

Does the ERNA Form 3 show any stock owned by director Robert J. Spiegel?

No. The Form 3 indicates zero holding entries for Robert J. Spiegel, meaning no reportable equity or derivative positions in Ernexa Therapeutics Inc. are listed in this filing.

Are there any insider buy or sell transactions disclosed for ERNA in this Form 3?

No. The transaction summary shows 0 buy transactions, 0 sell transactions, and 0 other transactions for this Form 3, so no insider trading activity is reported for Ernexa Therapeutics Inc. here.

Does the ERNA Form 3 disclose any derivative securities for Robert J. Spiegel?

No. The Form 3 lists 0 derivative transactions and an empty derivative summary, indicating no reportable options, warrants, or other derivatives for Robert J. Spiegel in this filing.

What insider role is reported in the ERNA Form 3?

The Form 3 identifies Robert J. Spiegel as a director of Ernexa Therapeutics Inc. (ERNA). He is not reported as an officer or a ten percent owner in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/22/2026 - 04:13 PM EDT Accepted by SEC EDGAR 09/22/2026 - 04:13 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Spiegel Robert J.

(Last) (First) (Middle)

C/O ERNEXA THERAPEUTICS INC.

1035 CAMBRIDGE STREET, SUITE 18A

(Street)

CAMBRIDGE MASSACHUSETTS 02141

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/14/2026

3. Issuer Name and Ticker or Trading Symbol
Ernexa Therapeutics Inc. [ ERNA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Robert Spiegel	09/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)